Results 1 to 10 of about 6,560 (205)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Viruses, 2022
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses.
Ashley Jia Wen Yip, Zheng Yao Low, Vincent T K Chow   +2 more
exaly   +4 more sources

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Metabolites, 2023
The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19.
Pankti C Balar, Vivek P Chavda, Lalitkumar K Vora   +2 more
exaly   +4 more sources

Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study [PDF]

Scientific Reports
This study evaluates the effect of molnupiravir on clinical improvement, viral clearance and antibody responses of COVID-19 patients who previously developed immunity through vaccination or prior infection.
Serap Şimşek-Yavuz, Alpay Azap, Gülsüm Öztürk-Emiral, Hüsna Çevik, Rahmet Güner, Müge Ayhan, Belgin Coşkun, Aysun Benli, Yeşim Tok, Mustafa Önel, İlker İnanç-Balkan, Sezen Fansa, Fatma Zehra Güneşer, Mahir Kapmaz, Nilsun Altunal, Elif Selcen Beng, Özlem Aydın, Sezen Özge Özen, Seniha Başaran, Hasan Yağmur, Meryem Çalışkan, Melek-Nur Aslan, Neslihan Uyar, Burcu Atasoy Bozan, Mihriban Aksoy, Mehtap Aydın, Duygu Korkut Akyürek, Elif Mukime Sarıcaoğlu, Önder Ergönül, Sevim Meşe, Füsun Can, Mert Ahmet Kuşkucu, Ali Ağaçfidan, Filiz Pehlivanoğlu, Özlem Altuntaş-Aydın, Alper Gündüz   +35 more
doaj   +2 more sources

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molecules, 2021
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq   +2 more
exaly   +3 more sources

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating.
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello   +2 more
exaly   +3 more sources

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study [PDF]

Clinical and Translational Science
Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
doaj   +2 more sources

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. [PDF]

Immun Inflamm Dis
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Kuo HT, Hsu AY, Liu DY, Wu BQ, Wei JC, Hsia NY, Shao YC, Lai CT, Chiang CC, Lin CJ, Chen HS, Wang YH, Tseng H, Hsu HC, Tsai YY.   +14 more
europepmc   +2 more sources

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness [PDF]

Viruses
Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms.
Yuriko Tomita, Kaya Miyazaki, Rika Mochizuki, Hideki Hasegawa   +3 more
doaj   +2 more sources

Why Molnupiravir Fails in Hospitalized Patients

mBio, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life.
Ashley N. Brown, Yinzhi Lang, Jieqiang Zhou, Evelyn J. Franco, Kaley C. Hanrahan, Juergen B. Bulitta, George L. Drusano   +6 more
doaj   +3 more sources

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]

BMC Infectious Diseases
Background COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin, Shwu-Jiuan Lin, Yu-Hui Chang, Fu-Der Wang, Phung-Anh Nguyen, Phan Thanh Phuc, Whitney Burton, Nguyen Thi Kim Hien, Chia-Chieh Lin, Carlos Shu-Kei Lam, To-Chi Ha, Christine Y. Lu, Chih-Wei Huang, Hsuan-Chia Yang, Shiue-Ming Lin, Chieh Yang, Li-Hsuan Wang, Jason C. Hsu   +17 more
doaj   +2 more sources